Two child deaths in China gene trials spur tighter rules

Two children have died in separate experimental gene-editing trials in China, drawing renewed scrutiny to the country's fast-track clinical research system and reigniting a global debate over the ethical guardrails governing cutting-edge biomedical treatments.

The deaths, detailed in a Nature editorial published September 7, have put a spotlight on so-called investigator-initiated trials, a category of study led by researchers rather than pharmaceutical companies that can begin without approval from China's national drug regulator.nature+1

The Cases

The first death, revealed in July by an investigation from Science and Retraction Watch, involved a six-year-old girl given the pseudonym "Mei." She died in March 2025, one week after receiving a spinal infusion of trillions of viral particles carrying a CRISPR-derived base editor intended to treat Snijders Blok-Campeau syndrome, a rare neurodevelopmental condition that is not life-threatening. Mei's parents paid more than $800,000 to fund the experiment. Seven experts who reviewed the case told Science the trial's risks were downplayed and that troubling primate data suggesting lethal outcomes were not adequately disclosed to the family. The hospital's ethics committee concluded her death from thrombotic microangiopathy was "without any doubt" linked to the therapy.crisprmedicinenews+3

The second death came to light in August after a monthslong STAT News investigation. A boy enrolled in a trial run by Shanghai-based HuidaGene Therapeutics for Duchenne muscular dystrophy died in August 2025 from acute respiratory distress syndrome following a severe immune reaction to a high-dose CRISPR therapy. The company did not disclose the death for roughly twelve months, until pressed by reporters.statnews+2

Oversight and Informed Consent

Both trials were investigator-initiated studies conducted under lighter regulatory oversight than industry-sponsored trials, which require approval from China's National Medical Products Administration. Writing in MedPage Today, bioethicists Emily Packard Dawson and Lainie Friedman Ross argued that the cases echo the 1999 death of Jesse Gelsinger in a U.S. gene-therapy trial and warned that translational speed cannot come "at the expense of the ethical and regulatory guardrails" protecting patients.geneticliteracyproject+3

China has since moved to tighten rules. Under a new government policy known as Order 818, only top-tier hospitals are permitted to conduct investigator-initiated trials for new biomedical technologies.nature

A Field at a Crossroads

The tragedies stand in contrast to the promise the technology has shown elsewhere. In the United States, "Baby KJ," treated in February 2025 at Children's Hospital of Philadelphia with a personalized base-editing therapy for a fatal metabolic disorder, continues to thrive. That divergence, researchers say, underscores that the science itself is not the problem — the failures lie in disclosure, consent, and oversight.pmc.ncbi.nlm.nih+1